Loading…
← CockpitCompetitor Analysis › 688108.SS Sino Medical Sciences Technology Inc. Class AOpen in the cockpit ↗

Sino Medical Sciences Technology Inc. Class A688108.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum laggard 13
Mkt cap
$753M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$14.0M
20-day average traded
Fwd P/E
60.0×
forward earnings
ROIC−WACC
+1.6 pp
WACC 14.1%
Hurdle
+18 pp
Req g minus delivered
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥12.16
1D-1.5%
1W-10.9%
1M-12.1%
3M-34.1%
6M-41.1%
YTD-36.8%
1Y-41.3%
ATR %4.6%
52w lowhigh53.7% off high

What Sino Medical Sciences Technology does

Employees: 649

Sino Medical Sciences Technology at a glance

Size Sino Medical Sciences Technology (688108.SS) is a China Health Care company (Medical Specialties) with a market value of $753M, the 2716th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.16 on 18 Nov 2026.

Performance Over six months the shares fell 41.1%, against -13.5% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 22.0% over the last twelve months (peer median +9.1%); the operating margin is 19.2% (peer median 12.7%).

Valuation It trades at 60.0× forward earnings against a peer median of 19.9× (2nd most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.6 points above its cost of capital (14.1% WACC).

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 88688108.SS 60
Six months, rebased to 100: Sino Medical Sciences Technology against the median of its 20 peers (local-currency closes).

Sino Medical Sciences Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥611MCN¥519MCN¥455MCN¥341MCN¥192M
Revenue growth—+14%+33%+78%—
Gross profitCN¥444MCN¥281MCN¥210MCN¥142MCN¥54.2M
EBITDAn/aCN¥142MCN¥57.4MCN¥12.9M-CN¥135M
Net incomeCN¥95.3MCN¥47.3MCN¥1.50M-CN¥39.6M-CN¥162M
Free cash flowCN¥193MCN¥116MCN¥61.3M-CN¥10.5M-CN¥221M
Capital expenditureCN¥29.6MCN¥45.8MCN¥70.0MCN¥67.7MCN¥111M
Total debtCN¥147MCN¥130MCN¥225MCN¥199MCN¥58.3M

Quarterly statements and history in the cockpit →

Sino Medical Sciences Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%300463002950300453603108INMD6008552190301367688179VREX1302CTKBMLABBBNXSETL3011223006226884107575096530688108.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Sino Medical Sciences Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×200×400×300463300453603108INMD2190301367VREX301122688410096530688108.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sino Medical Sciences Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%300463300453603108INMD219068817913027575096530688108.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sino Medical Sciences Technology is the large dot.

Sino Medical Sciences Technology competitors and peer comparison

How Sino Medical Sciences Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sino Medical Sciences Technology against its 20 peers (data as of 18 Nov 2026)
Measure688108.SSPeer medianRank in peer set
1-month return-12.1%-6.7%9th lowest of 21
6-month return-41.1%-13.5%2nd lowest of 21
Distance from 52-week high-53.7%-39.8%5th lowest of 21
Revenue growth (TTM)+22.0%+9.1%8th highest of 21
Operating margin19.2%12.7%3rd highest of 21
Forward P/E60.0×19.9×2nd most expensive of 16
Growth the price implies (Req g, 7 yrs)27.9%3.8%most demanding of 14
Growth delivered (Del g)+9.9%+13.2%5th lowest of 14
Hurdle (Req g minus delivered)+18.0 pp-9.8 pp3rd most demanding of 14
ROIC minus cost of capital+1.6 pp-0.3 pp9th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sino Medical Sciences Technology 688108.SSChina$753M-41%+22%19%60.0×27.9%+9.9%
Maccura Biotechnology 300463.SZChina$756M-18%-1%-4%421.0×7.9%-10.2%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%n/an/an/a
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%16.2×-1.9%+11.8%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%20.5×20.3%-0.2%
InMode INMDUnited States$741M-8%+2%18%9.8×-10.8%+12.4%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%n/an/an/a
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%14.4×3.8%+105.8%
BMC Medical 301367.SZChina$737M-17%+37%17%18.7×-1.5%+15.6%
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%27.4×17.1%+24.2%
Varex Imaging VREXUnited States$771M+79%+5%8%19.9×n/an/a
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%19.8×9.6%+15.5%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%n/an/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%11.5×21.3%+13.2%
Beta Bionics BBNXUnited States$779M+42%+44%-73%n/an/an/a
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%n/an/an/a
Caina Technology 301122.SZChina$721M+36%+61%0%55.4×n/an/a
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%22.8×-3.4%+15.7%
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%23.5×16.2%+25.9%
Japan Lifeline 7575.TJapan$703M+34%+6%19%14.5×-9.5%+2.9%
Seegene 096530.KSSouth Korea$808M-26%+13%13%20.0×-6.7%-15.9%

Questions

Which companies are Sino Medical Sciences Technology's closest peers?
The cockpit's peer set: Maccura Biotechnology (300463.SZ), Allmed Medical Products (002950.SZ), Jiang Xi Sanxin Medtec (300453.SZ), Shanghai Runda Medical Technology (603108.SS), InMode (INMD), Beijing Aerospace Changfeng (600855.SS), Zylox-Tonbridge Medical Technology (2190.HK), BMC Medical (301367.SZ).
Is Sino Medical Sciences Technology expensive compared with its peers?
On forward p/e it trades at 60.0× against a peer median of 19.9×, 2nd most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Sino Medical Sciences Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -41.1% against -13.5% for the median peer; over one year -41.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.